Pipeline PDF Print E-mail


Peregrine’s new class of phosphatidylserine (PS)-targeting antibodies target and bind to PS, a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of tumor cells and cells that line tumor blood vessels, causing the tumor to evade immune detection. Bavituximab is our lead therapeutic PS-targeting antibody candidate, which has demonstrated broad potential and represents a new approach to treating cancer. In preclinical studies, PS-targeting antibodies have demonstrated multiple signs of immune activation.

We are advancing the clinical development of bavituximab through company-sponsored trials as well as via strategic collaborations with recognized leaders in the oncology treatment field.

Products under investigation have not been approved for use outside the clinical trial setting. This information is presented only for the purposes of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes. ©2016 Peregrine Pharmaceuticals, Inc. All rights reserved.